Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Analytical evaluation of the clonoSEQ Assay for establishing measurable residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.

The paper reports analytical sensitivity and specificity of the clonoSEQ next-generation sequencing assay for measurable residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.

BMC CancerPubMed 32605647DOI 10.1186/s12885-020-07077-9